119th Congress · introduced in the Senate · Jan 29, 2025
PSA Screening for HIM Act
Official title from Congress.gov
Latest action (Mar 19, 2026): Committee on Health, Education, Labor, and Pensions. Hearings held.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
Cancer · Health care costs and insurance · Health care coverage and access · Health promotion and preventive care · Medical tests and diagnostic methods
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
27 citations; showing the 25 most recently posted.
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$1,790,000
Spent on own lobbying
…ll as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$510,000
Spent on own lobbying
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$510,000
Spent on own lobbying
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issue…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$1,240,000
Spent on own lobbying
…ll as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$590,000
Spent on own lobbying
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$590,000
Spent on own lobbying
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issue…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$2,300,000
Spent on own lobbying
…ll as their providers to better understand breast health. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VANDERBILT UNIVERSITY MEDICAL CENTER · lobbying firm or registrant: VANDERBILT UNIVERSITY MEDICAL CENTER
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$50,000
Spent on own lobbying
S.752, Accelerating Kids Access to Care Act. S.297, PSA Screening for HIM Act. H.R.5813, Womens Health and Cancer Rights Modernization Act of 2025 Issues related to the expiration of ACA Enhanced Premium Tax Cr…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$2,380,000
Spent on own lobbying
…and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Medicare/Medicaid
$980,000
Spent on own lobbying
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$980,000
Spent on own lobbying
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issue…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN UROLOGICAL ASSOCIATION · lobbying firm or registrant: VENABLE LLP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 9, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Specialty Physicians Advancing Rural Care Act (H.R. 4681 / S. 1380); PSA screening for HIM Act (H.R. 1300 / S. 297); Medicare physician payment issues; Telehealth policy issues; Price authorization issues; Medicine Patient Access & Practice Stabilization Act (H.R. 879); Pub…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Medicare/Medicaid
$850,000
Spent on own lobbying
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$850,000
Spent on own lobbying
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issue…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$2,130,000
Spent on own lobbying
…and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL ASSOCIATION OF NUCLEAR PHARMACIES · lobbying firm or registrant: BOSE PUBLIC AFFAIRS GROUP
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
Amount not reported
S. 297; HR 4317
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. View filing
AMERICAN UROLOGICAL ASSOCIATION · lobbying firm or registrant: VENABLE LLP
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 6, 2025 · issue area: Health Issues
$30,000
Paid to lobbying firm
Specialty Physicians Advancing Rural Care Act (H.R. 4681 / S. 1380); PSA screening for HIM Act (H.R. 1300 / S. 297); Medicare physician payment issues; Telehealth policy issues; Price authorization issues; Medicine Patient Access & Practice Stabilization Act (H.R. 879); Pub…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DENDREON PHARMACEUTICALS LLC · lobbying firm or registrant: THE MCMANUS GROUP
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$30,000
Paid to lobbying firm
Support for S. 297/H.R. 1300 - PSA Screening for HIM Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Medicare/Medicaid
$670,000
Spent on own lobbying
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$670,000
Spent on own lobbying
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issue…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$2,630,000
Spent on own lobbying
…and advance health equity in breast and cervical cancer. Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act, H.R. 1300, S. 297. Legislation to remove cost sharing of PSA testing for those at the highest risk of being diagnosed with prostate cancer. Lung Cancer Screening and Prevention…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) · lobbying firm or registrant: AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP)
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 22, 2025 · issue area: Health Issues
$4,830,000
Spent on own lobbying
…Gillen, Laura - access to reproductive technology H.R. 2404 - Remote Opioid Monitoring Act - Rep. Balderson, Troy - remote monitoring for opioid prescriptions S. 297 - PSA Screening for HIM Act - Sen. Boozman, John - Prostate screening coverage S. 339 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Co…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DENDREON PHARMACEUTICALS LLC · lobbying firm or registrant: THE MCMANUS GROUP
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Health Issues
$30,000
Paid to lobbying firm
Support for S. 297/H.R. 1300 - PSA Screening for HIM Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Medicare/Medicaid
$560,000
Spent on own lobbying
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs; H.R. 1300/S. 297 PSA screening bills; Issues related to IRA (Pub. L 117-169); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ASTELLAS PHARMA US, INC. · lobbying firm or registrant: ASTELLAS PHARMA US, INC.
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Health Issues
$560,000
Spent on own lobbying
…utical Innovation and Patient Policy Issues (no specific bills); Issues pertaining to Current Procedural Terminology (CPT) codes (no specific bills); H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to m…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing